| Improve identification of preclinical studies required to bring agents to trials. |
|
|
|
|
|
|
| Identify the surgical window of opportunity for trials to evaluate if agents should be taken forward for additional testing. |
|
|
|
|
|
|
| Implement recent advances in targeted therapies and immunotherapies for gliomas. |
|
|
|
|
|
|